The small molecule inhibitor VX‐765 can covalently modify the Cys285 of caspase‐1, effectively inhibiting caspase‐1 activity and abnormal NLRP3 inflammasome activation in MS model MФ and MG [101]. Here, NLRP3 is linked to myeloid sarcoma.